Vesicular shunt for the drainage of excess fluid

Information

  • Patent Grant
  • 8394048
  • Patent Number
    8,394,048
  • Date Filed
    Tuesday, January 15, 2008
    17 years ago
  • Date Issued
    Tuesday, March 12, 2013
    11 years ago
  • Inventors
  • Original Assignees
  • Examiners
    • Zalukaeva; Tatyana
    • Marcetich; Adam
    Agents
    • Foley & Lardner LLP
    • Pisano; Nicola A.
    • Bolten; Christopher C.
Abstract
A transvesicular drainage device configured to drain excess fluid from a variety of locations in the human body into the bladder. The device may be used to treat ascites or any fluid collection within the body of a human or of a non-human mammal.
Description
FIELD OF THE INVENTION

The present invention relates to a transvesicular drainage device designed to drain excessive fluid from a bodily cavity into the bladder. More particularly, the present invention relates to a vesicular drainage device that may be coupled to the bladder's wall and control flow of excess fluid from a region of the body into the bladder.


BACKGROUND OF THE INVENTION

In medicine there are a variety of conditions which result in pathologic chronic collection of bodily fluids. Chronic pericardial effusions, normopressure hydrocephalus, hydrocephalus, chronic pulmonary effusion, and ascites are but a few of the conditions in which chronic fluid collections persist and result in increased morbidity and mortality. These conditions currently are treated by different methods, more particularly: (1) external drainage with a high-risk of infection and long-term requirement for multiple punctures, (2) drainage to another body-cavity, or (3) various drugs.


For pericardial effusions and hydrocephalus of all types, the treatment of choice is drainage to another region of the body. This treatment entails a pericardial window, a highly invasive procedure in which a large section of the external heart cavity is removed. For hydrocephalus, the treatment of choice typically involves the use of a ventriculo-peritoneal shunt draining the cerebrospinal fluid into the peritoneal cavity. Unfortunately, this device frequently becomes clogged due to the proteinaceous environment of the peritoneal cavity and requires removal or revision.


More particularly, ascites is a highly debilitating complication associated with many medical conditions including liver failure and congestive heart failure. Untreated ascites can result in respiratory compromise, compression of the inferior vena cava (a vital blood vessel) and spontaneous bacterial peritonitis (a life-threatening condition). In order to treat chronic ascites, medicine has turned to both drugs and surgery.


The drugs required to treat ascites are typically long-term and frequently result in complications. The most common pharmaceutical treatment of ascites involves the use of diuretics to remove fluid from patient's body through their urine. The difficulty with this treatment is that fluid is removed from the entire body, including the circulating volume of blood, and can result in excessive loss of fluid required to perfuse the vital organs of the human body. Thus, even with religious application, drug treatments frequently fail and surgical, or invasive, procedures become necessary.


The current treatment of choice is called paracentesis. In paracentesis, the peritoneal fluid is drained through the abdominal wall via the insertion of a needle through the abdominal wall into the peritoneal cavity. Unfortunately, this procedure is only a temporary fix as the ascites quickly refills the peritoneal cavity in most chronic conditions. Furthermore, repeated paracenteses put the patient at increased risk for a life-threatening infection of their peritoneal cavity. Other surgical/invasive procedures involve treatment of the cause of the ascites (for example the Transjugular Intrahepatic Portosystemic Shunt) but these measures also frequently result in complications, which are often serious, and are thus performed hesitantly.


None of the existing devices are able to drain the peritoneal cavity except through temporary transabdominal insertion of a drainage catheter. These devices provide little improvement over the intermittent punctures of paracentesis and result in increased rates of infection if left in place for any length of time. The present invention will obviate the need for a long-term abdominal incision and, therefore, will eliminate the associated increased risk of serious infection.


SUMMARY OF THE INVENTION

The present invention relates to a device designed for implantation in the wall of the bladder that permits the drainage of excessive fluid into the bladder.


In one embodiment, this device includes a hollow, cylindrical column with flanges at both ends to provide secure anchorage in the bladder wall. Preferably there is a mechanism to provide unidirectional flow of fluid and prevent reflux of urine inside the column. A preferred embodiment of the device provides a passive ball-valve mechanism, which allows for drainage of fluid into the bladder whenever a certain pressure is achieved at the collection site. Another preferred embodiment of the device provides an active valve mechanism, which allows for controlled drainage of fluid into the bladder whenever the valve is actuated. The most preferred embodiment of the device includes a pump in addition to an active valve mechanism.


The present invention avoids the difficulties associated with the current therapies for chronic ascites, namely, the procedure allows the drainage of peritoneal fluid without (1) the serious complications of pharmaceuticals, (2) the inconvenience, the substantial costs and the increased risk of infection associated with frequent paracenteses, and (3) the multiple severe complications associated with more invasive and risky surgical operations to treat the cause of ascites.


When used to treat ascites, a device according to the present invention can be implanted either through a transurethral or transabdominal route. In order to drain other sites, the bladder component is implanted as above, and a flexible tube or other conduit may be incorporated to place the receptacle end of the device in a fashion tailored to the region to be drained. More specifically, such embodiment pertains to a peritoneo-vesicular drainage device permitting unidirectional flow of peritoneal fluid from the peritoneal cavity into the bladder.


In all embodiments, it is preferred that the device be constructed with biocompatible materials.


Methods of use of devices according to the present invention are also disclosed herein.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a cross-sectional view of a device according to an embodiment of the present invention.



FIG. 2 shows a cross-sectional view of the device of FIG. 1 to treat ascites 1 after implantation, when the peritoneal pressure is sufficient to permit drainage.



FIG. 3 shows a cross-sectional view of the device of FIG. 1 to treat ascites after implantation, when the peritoneal pressure is not sufficient to open the valve and no fluid flow occurs.



FIG. 4 is an illustration of an example of an insertion device through which a device according to the present invention can be implanted in the bladder wall.



FIG. 5 is an illustration of alternative embodiments of the invention with differing valve types, differing valve positioning and differing number of valves.



FIG. 6 is an illustration of an alternative embodiment of a device according to the present invention, in which an active, externally or internally controlled valve is utilized.



FIG. 7 is an illustration of an alternative embodiment of a device according to the present invention, in which a pump is included along the length of the tubing and placed subcutaneously for external control of drainage with a passive valve.



FIG. 8 is an illustration of a few of the alternative embodiment of a device according to the present invention, in which the peritoneal cavity, the pulmonary space and the ventricular space are able to be drained (pericardial drainage device not shown).





DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

As can be seen in FIG. 1, a first embodiment of the present invention provides a novel vesicular drain 1 for implantation in the bladder wall 9, allowing unidirectional drainage of fluid into the bladder. The drain 1 includes two flanges at its ends 2, 3, which provide for the device to be firmly anchored once placed across the bladder wall 9. Alternative embodiments of the device may use other anchoring mechanisms, including, but not limited to: a screw thread on the outside of 1, staples, sutures, an adhesive compound, and/or one or more barbs.


The hollow shaft of the device contains a ball-valve 4 through which a positive closing pressure is provided by an attached spring 5.


The fluid collection interface of the device 1 may optionally include a large pore mesh 6 to allow for free flow of fluid while preventing incarceration of tissues at the drainage site.


As can be seen in FIG. 2, once the pressure of the fluid collection (in this case the peritoneal cavity) 7 exceeds the combined force of the spring 5 and the pressure of the fluid-filled bladder cavity 8, the peritoneal fluid 19 flows into the bladder cavity 8 through displacement of the ball-valve 4. There, the peritoneal fluid mixes with the urine 20.


If the pressure of the bladder cavity 8 and the force of the spring 5, though, are greater than the pressure of the fluid collection (in this case the peritoneal cavity) 7, then the valve 4 will remain closed preventing reflux of urine 19 into the peritoneal cavity as depicted in FIG. 3.


The device is designed to be placed transurethrally or transabdominally via an insertion device 10 such as that depicted in FIG. 4. The method of insertion allows for a single invasive procedure to provide a long-term solution to the otherwise difficult problem of refractory, chronic ascites.


Alternatively, the device may contain a length of tubing 11 or other means of fluid transport to reach the fluid collection as well as an optional perforated receptacle 12, 17 and 18 through which the fluid collection will drain into the tubing. Such other means of fluid transport include, but are not limited to, conduit, catheter, channel, lumen, hose, pipe, duct, artery or vessel. The device may contain one or more valves of a variety of types including passive valves 4, 13 (flapper-valve), 14 (in FIG. 5), or active valves 15 (in FIG. 6) for tighter control of fluid drainage.


The device is also designed to be able to incorporate a pump mechanism 16 as shown in FIG. 7 which, when placed subcutaneously, can be actuated to provide an active pumping mechanism with the passive valves 4, 13, 14, or with an active valve 15. A third embodiment of the invention involves a unidirectional pump in place of the valve, controlling the flow of fluid through the device. A fourth embodiment of the invention involves a single unidirectional valve controlling the flow of fluid through the device.


Alternatively, maneuvers which increase the pressure of the fluid cavity can also be utilized with the passive valves 4, 13, 14 to affect drainage such as bearing down to increase intraabdominal pressure to drain the peritoneal cavity or application of a girdle designed to increase abdominal pressure.


The device will be designed to drain a variety of different fluid collections including, but not limited to, the peritoneal cavity FIG. 8A, pulmonary effusions FIG. 8B and excessive cerebrospinal fluid FIG. 8C. Pericardial effusion drain is not shown.


Of particular interest to the inventors is the use of the invention to drain pulmonary effusions and other fluid collections in the lungs, in FIG. 8B.


While these are the preferred embodiments, the device could employ any mechanism which provides a unidirectional passive or active valve for the drainage of any body fluid into the urinary bladder. This could involve filtration of the fluid through a polymer so as to sequester albumin and other proteins in the fluid collection while allowing flow of water and ions across the semi-permeable membrane. This could also involve an electronic valve triggered via communication across the tissues of the human body through EMFs such as radio, electricity, pressure, mechanical, magnetism, or other means of communication, allowing drainage only at selected times.


The valve of the device can take many shapes and the device can be manufactured from any of a variety of materials with the only requirement being that of biocompatibility. Alternatively, the device, in either the active or passive embodiment, may incorporate anti-infective components in order to prevent the spread of infection between the body cavities. Such anti-infective components include, but are not limited to, bacteriostatic materials, bacteriocidal materials, one or more antibiotic dispensers, antibiotic eluting materials, entrained radioisotopes, a heating element, bioactive plastics, surfaces which encourage epithelialization, and coatings which prevent bacterial adhesion.


Alternatively, the device, in either the active or passive embodiment, may incorporate anti-clogging components. Such anti-clogging components include, but are not limited to, an active ultrasonic component, an inner and outer sleeve which, when actively agitated, disrupt the inner lumen, surfaces which encourage epithelialization, enzyme eluting materials, enzyme eluting materials which specifically target the proteinaceous components of ascites, chemical eluting surfaces, an intermittent plunger mechanism, and coatings which prevent adhesion of proteinaceous compounds.


While the device is primarily contemplated for use in human patients, the inventors also contemplate that the invention will have veterinary uses or product development purposes in equine, bovine, canine, feline, and other mammalian species.


Further, while the invention has been described in connection with the above described embodiments, it is not intended to limit the scope of the invention to the particular forms set forth, but on the contrary, it is intended to cover such alternatives, modifications, and equivalents as may be included within the scope of the invention. Still further, the scope of the present invention fully encompasses other embodiments that may become obvious to those skilled in the art and the scope of the present invention is limited only by the appended claims.

Claims
  • 1. Apparatus for draining excess fluid from a patient's peritoneal cavity comprising: a hollow cylinder configured to be disposed across a wall of a patient's bladder, the hollow cylinder having an inflow end and an outflow end including a deformable flange configured to be deployed and anchored within the bladder;an implantable pump having an inlet port and an outlet port;a first elongated flexible tube coupled in fluid communication between the inflow end of the hollow cylinder and the outlet port of the implantable pump;a second elongated flexible tube having an exterior diameter, an outlet end coupled to the inlet port of the implantable pump, and an inlet end;a perforated receptacle coupled to the inlet end of the second elongated flexible tube, the perforated receptacle having a substantially greater diameter than the exterior diameter of the second elongated flexible tube and a multiplicity of pores configured to permit inflow of peritoneal fluid into the perforated receptacle while retarding ingrowth of tissue; andan electronic valve regulating flow of fluid between the outlet end of the implantable pump and the outflow end of the hollow cylinder,wherein the apparatus is configured to be triggered via an electric or radio signal.
  • 2. The apparatus of claim 1, wherein the electronic valve is disposed within the hollow cylinder.
  • 3. The apparatus of claim 1, wherein the deformable flange facilitates coupling of the hollow cylinder to the wall of the bladder.
  • 4. The apparatus of claim 1, wherein the perforated receptacle comprises a mesh.
  • 5. The apparatus of claim 1, wherein the electronic valve is controlled through a signal selected from the group of a pressure signal, a mechanical signal, a magnetic signal, an electric signal, and an electromagnetic frequency (EMF) signal.
  • 6. The apparatus of claim 5, wherein the EMF signal is a radio signal.
  • 7. The apparatus of claim 1, wherein the apparatus is configured to provide unidirectional flow of the fluid.
  • 8. The apparatus of claim 1, wherein the apparatus is configured to prevent the spread of infection.
  • 9. The apparatus of claim 8, wherein the apparatus is configured to prevent the spread of infection by providing one or more antibiotic dispensers.
  • 10. The apparatus of claim 8, wherein the apparatus is configured to prevent the spread of infection by providing a material selected from the group consisting of a bacteriostatic material, a bacteriocidal material, an antibiotic eluting material, a material comprising entrained radioisotopes, a material comprising a heating element, a bioactive plastic, and a surface encouraging epithelialization.
  • 11. The apparatus of claim 8, wherein the apparatus is configured to prevent the spread of infection by providing a coating that prevents bacterial adhesion.
  • 12. The apparatus of claim 1, further comprising an anti-clogging device.
  • 13. The apparatus of claim 12, wherein the anti-clogging device is selected from the group consisting of an active ultrasonic component, a sleeve disrupting the flow of the fluid upon active agitation, a surfaces encouraging epithelialization, an enzyme eluting material, a chemical eluting surface, an intermittent plunger mechanism, and a coating preventing adhesion of proteinaceous compounds.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of U.S. application Ser. No. 10/369,550 filed on Feb. 21, 2003, which claims the priority of U.S. Provisional Application Ser. No. 60/359,287 filed on Feb. 25, 2002 and U.S. Provisional Application Ser. No. 60/389,346 filed on Jun. 18, 2002, the entireties of which are incorporated herein by reference.

US Referenced Citations (99)
Number Name Date Kind
3516410 Hakim Jun 1970 A
3540451 Zeman Nov 1970 A
3575158 Summers Apr 1971 A
3608088 Dorman et al. Sep 1971 A
3626950 Schulte Dec 1971 A
3642004 Osthagen et al. Feb 1972 A
3654932 Newkirk et al. Apr 1972 A
3810259 Summers May 1974 A
3910283 Leveen Oct 1975 A
4083786 Tsuda et al. Apr 1978 A
4261341 Hakim et al. Apr 1981 A
4368737 Ash Jan 1983 A
4416657 Berglund Nov 1983 A
4418693 LeVeen et al. Dec 1983 A
4557724 Gregonis et al. Dec 1985 A
4584994 Bamberger et al. Apr 1986 A
4595390 Hakim et al. Jun 1986 A
4610625 Bunn Sep 1986 A
4610658 Buchwald et al. Sep 1986 A
4615691 Hakim et al. Oct 1986 A
4618343 Polaschegg Oct 1986 A
4657530 Buchwald et al. Apr 1987 A
4725207 Buchwald et al. Feb 1988 A
4779614 Moise Oct 1988 A
4850955 Newkirk Jul 1989 A
4904236 Redmond et al. Feb 1990 A
4950232 Ruzicka et al. Aug 1990 A
4963129 Rusch Oct 1990 A
4991594 Angelchik Feb 1991 A
5021048 Buckholtz Jun 1991 A
5037385 O'Byrne Aug 1991 A
5071408 Ahmed et al. Dec 1991 A
5078688 Lobodzinski et al. Jan 1992 A
5147281 Thornton et al. Sep 1992 A
5167615 East et al. Dec 1992 A
5254084 Geary Oct 1993 A
5356386 Goldberg et al. Oct 1994 A
5360414 Yarger Nov 1994 A
5385541 Kirsch et al. Jan 1995 A
5387188 Watson et al. Feb 1995 A
5395350 Summers Mar 1995 A
5397354 Wilk et al. Mar 1995 A
5431637 Okada et al. Jul 1995 A
5472323 Hirabayashi et al. Dec 1995 A
5474683 Bryant et al. Dec 1995 A
5489276 Jamshidi Feb 1996 A
5520632 Leveen et al. May 1996 A
5575770 Melsky et al. Nov 1996 A
5637083 Bertrand et al. Jun 1997 A
5725506 Freeman et al. Mar 1998 A
5830172 Leveen et al. Nov 1998 A
5902336 Mishkin May 1999 A
5947911 Wong et al. Sep 1999 A
5980478 Gorsuch et al. Nov 1999 A
5980480 Rubenstein et al. Nov 1999 A
5989207 Hughes Nov 1999 A
6007511 Prywes Dec 1999 A
6017355 Hessel et al. Jan 2000 A
D420738 Carter et al. Feb 2000 S
6022333 Kensey Feb 2000 A
6027442 Von Iderstein Feb 2000 A
6132415 Finch et al. Oct 2000 A
6162238 Kaplan et al. Dec 2000 A
6162487 Darouiche Dec 2000 A
6193684 Burbank et al. Feb 2001 B1
6254567 Treu et al. Jul 2001 B1
6264625 Rubenstein et al. Jul 2001 B1
6417750 Sohn Jul 2002 B1
6436087 Lewis et al. Aug 2002 B1
6533733 Hylton et al. Mar 2003 B1
6648906 Lasheras et al. Nov 2003 B2
6689085 Rubenstein et al. Feb 2004 B1
6827682 Bugge et al. Dec 2004 B2
6846168 Davis Jan 2005 B2
6875192 Saul et al. Apr 2005 B1
6887214 Levin et al. May 2005 B1
6894456 Tsukamoto et al. May 2005 B2
6905474 Borgensen Jun 2005 B2
6926691 Miethke Aug 2005 B2
6955655 Burbank et al. Oct 2005 B2
7025739 Saul Apr 2006 B2
7025742 Rubenstein et al. Apr 2006 B2
7128735 Weston Oct 2006 B2
7195608 Burnett Mar 2007 B2
7311690 Burnett Dec 2007 B2
7335179 Burnett Feb 2008 B2
7419483 Shehada Sep 2008 B2
20010025170 Paderni Sep 2001 A1
20020013545 Soltanpour et al. Jan 2002 A1
20020022793 Bertrand et al. Feb 2002 A1
20020107467 Levin Aug 2002 A1
20040049288 Levin Mar 2004 A1
20050096582 Burnett May 2005 A1
20050131340 Sorenson et al. Jun 2005 A1
20050273034 Burnett Dec 2005 A1
20060036208 Burnett Feb 2006 A1
20060058731 Burnett et al. Mar 2006 A1
20070106205 Connell et al. May 2007 A1
20080108935 Nyhart, Jr. May 2008 A1
Foreign Referenced Citations (3)
Number Date Country
2 350 794 Dec 2000 GB
WO 9741799 Nov 1997 WO
WO 9816171 Apr 1998 WO
Non-Patent Literature Citations (44)
Entry
Rozenblit, Grigory N., Peritoneal-Urinary Drainage for Treatment of Refractory Ascites: A Pilot Study, Journal of Vascular & Interventional Radiology, Nov./Dec. 1998, 9(6):998-1005, NY.
U.S. Appl. No. 11/933,214, filed Oct. 31, 2007, Burnett.
Costanzo et al., “Early Ultrafiltration in Patients with Decompensated Heart Failure and Diuretic Resistance,” J. Am. Coll. Cardiol., vol. 46 (11), pp. 2047-2051 (2005).
Fioulberg et al., “Terminal Right Heart Failure Due to Complex Congenital Cardiac Disease Successfully Managed by Ilome Peritoneal Drainage,” Cardiol. Young, vol. 13, pp. 568-570 (2003).
Ortiz et al., “Long-Term Automated Peritoneal Dialysis in Patients with Refractory Congestive Heart Failure,” Advances in Peritoneal Dialysis, vol. 19, pp. 77-80 (2003).
International Search Report for PCT/US03/05145, 3 pages (mailed Jul. 17, 2003).
USPTO, Supplemental Notice of Allowability for U.S. Appl. No. 10/369,550, 2 pages (mailed Dec. 17, 2007).
USPTO, Notice of Allowance and Fees Due for U.S. Appl. No. 10/369,550, 4 pages (mailed Sep. 24, 2007).
USPTO, Non-Final Office Action for U.S. Appl. No. 10/369,550, 13 pages (mailed Mar. 09, 2006).
USPTO, Corrected Notice of Allowance and Fees Due for U.S. Appl. No. 10/700,863, 5 pages (mailed Nov. 08, 2007).
USPTO, Notice of Allowance and Fees Due for U.S. Appl. No. 10/700.863, 7 pages (mailed Nov. 2, 2006).
USPTO, Non-Final Office Action for U.S. Appl. No. 10/700,863, 11 pages (mailed Feb. 2, 2006).
USPTO, Supplemental Notice of Allowability for U.S. Appl. No. 11/198,079, 2 pages (mailed Jan. 9, 2007).
USPTO, Notice of Allowance and Fees Due for U.S. Appl. No. 11/198,079, 4 pages (mailed Oct. 5, 2006).
USPTO, Non-Final Office Action for U.S. Appl. No. 11/198,079, 7 pages (mailed Feb. 2, 2006).
USPTO, Non-Final Office Action for U.S. Appl. No. 11/181,539, 10 pages (mailed Sep. 16, 2008).
USPTO, Final Office Action for U.S. Appl. No. 11/181,539, 10 pages. (mailed Mar. 18, 2008).
USPTO, Non-Final Office Action for U.S. Appl. No. 11/181,539, 8 pages (mailed May 22, 2007).
USPTO, Final Office Action for U.S. Appl. No. 11/181,539, 6 pages (mailed Oct. 10, 2006).
USPTO, Non-Final Office Action for U.S. Appl. No. 11/181,539, 8 pages (mailed Jan. 7, 2006).
USPTO, Final Office Action for U.S. Appl. No. 10/826,237, 10 pages (mailed Oct. 28, 2008).
USPTO, Non-Final Office Action for U.S. Appl. No. 10/826,237, 10 pages (mailed Feb. 22, 2008).
USPTO, Final Office Action for U.S. Appl. No. 10/826,237, 10 pages (mailed Jul. 5, 2007).
USPTO, Non-Final Office Action for U.S. Appl. No. 10/826,237, 8 pages (mailed Dec. 19, 2006).
USPTO, Office Action mailed Dec. 19, 2006, U.S. Appl. No. 10/826,237.
USPTO, Final Office Action mailed Jul. 05, 2007, U.S. Appl. No. 10/826,237.
USPTO, Advisory Action mailed Nov. 20, 2007, U.S. Appl. No. 10/826,237.
USPTO, Office Action mailed Feb. 22, 2008, U.S. Appl. No. 10/826,237.
USPTO, Final Office Action mailed Oct. 28, 2008, U.S. Appl. No. 10/826,237.
USPTO, Office Action mailed Apr. 13, 2009, U.S. Appl. No. 10/826,237.
USPTO, Office Action mailed Jan. 27, 2006, U.S. App. No. 11/181,539.
USPTO, Final Office Action mailed Oct. 10, 2006, U.S. Appl. No. 11/181,539.
USPTO, Office Action mailed May 22, 2007, U.S. Appl. No. 11/181,539.
USPTO, Final Office Action mailed Mar. 18, 2007, U.S. Appl. No. 11/181,539.
USPTO, Office Action mailed Sep. 16, 2008, U.S. Appl. No. 11/181,539.
USPTO, Notice of Allowance with reasons for allowance mailed Jul. 20, 2009, U.S. Appl. No. 11/181,539.
USPTO, Final Office Action mailed Dec. 13, 2006, U.S. Appl. No. 10/369,550, 4 pages.
USPTO, Non-Final Office Action mailed Mar. 9, 2006, U.S. Appl. No. 10/369,550, 13 pages.
USPTO, Notice of Allowance with reasons for allowance mailed Jul. 20, 2009, U.S. Appl. No. 11/181,539, 9 pages.
USPTO, Advisory Action mailed Jul. 14, 2008, U.S. Appl. No. 11/181,539, 3 pages.
USPTO, Non-Final Office Action mailed Jan. 27, 2006, U.S. Appl. No. 11/181,539, 8 pages.
USPTO, Final Office Action mailed Jan. 05, 2010, U.S. Appl. No. 10/826,237, 13 pages.
USPTO, Advisory Action mailed Nov. 20, 2007, U.S. Appl. No. 10/826,237, 3 pages.
USPTO, Non-Final Office Action mailed Apr. 6, 2010, U.S. Appl. No. 11/933,214, 18 pages.
Related Publications (1)
Number Date Country
20080154173 A1 Jun 2008 US
Provisional Applications (2)
Number Date Country
60359287 Feb 2002 US
60389346 Jun 2002 US
Divisions (1)
Number Date Country
Parent 10369550 Feb 2003 US
Child 12014696 US